BACKGROUND: Current evidence suggests that asthma patients with the ADRB2 Arg16 genotype have a poorer response to long-acting β2-agonists (LABA), but the results remain inconsistent. AIM: This study assessed the association between Arg16 variants and treatment outcome in children treated with inhaled corticosteroids (ICS) and LABA. MATERIALS & METHODS: ADRB2 Arg16 was genotyped in 597 children (4-12 years of age) participating in the PACMAN cohort study. A questionnaire was used to assess asthma control, frequency of asthma-related emergency department visits and use of oral corticosteroids in the past year. RESULTS: Arg/Arg carriers with a reported use of ICS and LABA had an increased risk of oral corticosteroid use (odds ratio: 14.9; 95% CI: 1.59-140.1) and emergency department visits in the past year (odds ratio: 11.9; 95% CI: 1.22-115.8) compared to Gly/Gly carriers. This effect was not observed in Arg/Arg genotype carriers reporting ICS use only. CONCLUSION: Children who are homozygous for ADRB2 Arg16 have an increased risk of exacerbations when treated with combined LABA and ICS.
BACKGROUND: Current evidence suggests that asthmapatients with the ADRB2Arg16 genotype have a poorer response to long-acting β2-agonists (LABA), but the results remain inconsistent. AIM: This study assessed the association between Arg16 variants and treatment outcome in children treated with inhaled corticosteroids (ICS) and LABA. MATERIALS & METHODS:ADRB2Arg16 was genotyped in 597 children (4-12 years of age) participating in the PACMAN cohort study. A questionnaire was used to assess asthma control, frequency of asthma-related emergency department visits and use of oral corticosteroids in the past year. RESULTS:Arg/Arg carriers with a reported use of ICS and LABA had an increased risk of oral corticosteroid use (odds ratio: 14.9; 95% CI: 1.59-140.1) and emergency department visits in the past year (odds ratio: 11.9; 95% CI: 1.22-115.8) compared to Gly/Gly carriers. This effect was not observed in Arg/Arg genotype carriers reporting ICS use only. CONCLUSION:Children who are homozygous for ADRB2Arg16 have an increased risk of exacerbations when treated with combined LABA and ICS.
Authors: Niloufar Farzan; Susanne J Vijverberg; Anand K Andiappan; Lambang Arianto; Vojko Berce; Natalia Blanca-López; Hans Bisgaard; Klaus Bønnelykke; Esteban G Burchard; Paloma Campo; Glorisa Canino; Bruce Carleton; Juan C Celedón; Fook Tim Chew; Wen Chin Chiang; Michelle M Cloutier; Denis Daley; Herman T Den Dekker; F Nicole Dijk; Liesbeth Duijts; Carlos Flores; Erick Forno; Daniel B Hawcutt; Natalia Hernandez-Pacheco; Johan C de Jongste; Michael Kabesch; Gerard H Koppelman; Vangelis G Manolopoulos; Erik Melén; Somnath Mukhopadhyay; Sara Nilsson; Colin N Palmer; Maria Pino-Yanes; Munir Pirmohamed; Uros Potočnik; Jan A Raaijmakers; Katja Repnik; Maximilian Schieck; Yang Yie Sio; Rosalind L Smyth; Csaba Szalai; Kelan G Tantisira; Steve Turner; Marc P van der Schee; Katia M Verhamme; Anke H Maitland-van der Zee Journal: Pharmacogenomics Date: 2017-06-22 Impact factor: 2.533
Authors: Steve Turner; Ben Francis; Nuha Wani; Susanne Vijverberg; Maria Pino-Yanes; Somnath Mukhopadhyay; Roger Tavendale; Colin Palmer; Esteban G Burchard; Simon Kebede Merid; Erik Melén; Anke H Maitland-van der Zee; On Behalf Of The Pharmacogenomics In Childhood Asthma Consortium Journal: Pharmacogenomics Date: 2018-05-22 Impact factor: 2.533
Authors: Steve Turner; Ben Francis; Susanne Vijverberg; Maria Pino-Yanes; Anke H Maitland-van der Zee; Kaninika Basu; Lauren Bignell; Somnath Mukhopadhyay; Roger Tavendale; Colin Palmer; Daniel Hawcutt; Munir Pirmohamed; Esteban G Burchard; Brian Lipworth Journal: J Allergy Clin Immunol Date: 2016-01-07 Impact factor: 10.793
Authors: Leila Karimi; Susanne J Vijverberg; Marjolein Engelkes; Natalia Hernandez-Pacheco; Niloufar Farzan; Patricia Soares; Maria Pino-Yanes; Andrea L Jorgensen; Celeste Eng; Somnath Mukhopadhyay; Maximilian Schieck; Michael Kabesch; Esteban G Burchard; Fook Tim Chew; Yang Yie Sio; Uroš Potočnik; Mario Gorenjak; Daniel B Hawcutt; Colin N Palmer; Steve Turner; Hettie M Janssens; Anke H Maitland-van der Zee; Katia M C Verhamme Journal: Clin Exp Allergy Date: 2021-07-20 Impact factor: 5.401
Authors: Amber Dahlin; Joshua Denny; Dan M Roden; Murray H Brilliant; Christie Ingram; Terrie E Kitchner; James G Linneman; Christian M Shaffer; Peter Weeke; Hua Xu; Michiaki Kubo; Mayumi Tamari; George L Clemmer; John Ziniti; Michael J McGeachie; Kelan G Tantisira; Scott T Weiss; Ann Chen Wu Journal: Immun Inflamm Dis Date: 2015-07-14